

# Definitive Radiotherapy for Vaginal Angiomyofibroblastoma

Dr Rashmi S<sup>1</sup>, Dr Vaishnavi P Reddy<sup>2</sup>, Dr Kiran Kumar B R<sup>3</sup>, Dr Sanjeet K Mandal<sup>4</sup>

**Abstract:** Angiomyofibroblastoma (AMF) is a rare, benign, mesenchymal tumour occurring mainly in the vulva region of women. These tumours occur primarily on vagina, vulva, perineum, uterine cervix and the inguinoscrotal regions of men. There are only few cases described with primary occurrence in the pelvis or retroperitoneum. The goal of management is complete resection of tumour, but incomplete or partial resection is acceptable, especially when high operative morbidity due to extensive surgery is anticipated and preservation of fertility is an issue. Most of these tumours show oestrogen and progesterone receptor positivity and are likely to be hormone dependent. Several beneficial results with gonadotropin-releasing hormone (GnRH) agonist have been described in primary treatment of small tumours, as adjuvant therapy for residual tumour, pre-operatively to shrink tumours or even in the treatment of recurrence. However, there are no conclusive data as to the effectiveness of hormonal therapy/ oophorectomy in the treatment of these tumours. There are no supporting data for use of chemotherapy in patients with AMF. Radiotherapy may be good alternative to surgery; for unresectable, medically inoperable or recurrent tumours, and also patients unresponsive to embolization or hormonal therapy requiring morbid surgery. This case report describes the unique role of definitive radiotherapy for recurrent unresectable angiomyofibroblastoma of vagina in a young woman; and remains complete response for 20 months. We emphasize the role of definitive radiotherapy for patients with angiomyofibroblastoma of vagina and other pelvic sites that are not amenable for surgery, with benefits of good local control and organ preservation.

**Keywords:** Angiomyofibroblastoma, Vagina, Radiotherapy

## 1. Introduction


Angiomyofibroblastoma (AMF) is a rare and benign soft tissue tumour first described by Fletcher et al. in 1992. It belongs to the group of genital mesenchymal tumors mostly occurring in lower genital tracts of young to middle-aged women (1). These tumours occur primarily on vagina, vulva, perineum and uterine cervix (2-4) and the inguinoscrotal regions of men (5). There are only few cases described with primary occurrence in the pelvis or retroperitoneum (6,7). It should be differentiated from aggressive angiofibroma, cellular angiofibroma, and other myxoid tumors of genital tract (8), in which radical surgical treatment is needed. We report a case of young post hysterectomised women with recurrent unresectable aggressive angiomyofibroblastoma treated with primary radiotherapy.

## 2. Case Report

A 29 years old female with para 2 and living 2 presented to department of oncology, Vydehi Institute of Medical Sciences and Research Center, Bengaluru with complains of mass and bleeding per vagina since 5 months in Jan, 2016. There was no history of pain abdomen and abdominal distension/ altered bowel or bladder movements or loss of weight appetite. She had no associated comorbidities either. She had undergone hysterectomy for uterine fibroid in Jan 2014. The per vagina examination showed about 5x5x5cm sized mobile polypoidal growth seen in the right lateral and posterior wall of vagina till introitus. The excision biopsy was reported as Angiomyofibroblastoma of vagina. Patient had undergone wide local excision of the tumour and follow up was advised.

Later in May 2016, she again presented with mass per vagina and bleeding. The per vaginal examination revealed a recurrent firm growth measuring 5x5x7cm on the right lateral vaginal wall extending till the vault, which bleeds on


touch. The new histopathology of the biopsied growth revealed alternating hypercellular and hypocellular edematous regions with abundant blood vessels. There is minimal nuclear atypicity. The immunohistochemistry reported strongly positive for actin, vimentin, CD34, ER/PR, and negative for desmin; suggestive of angiofibroma. Magnetic Resonance Imaging (MRI) of pelvis revealed post hysterectomy status with an ill-defined heterogeneously enhancing polypoidal T2 hyperintense lesion of size 45x43x86mm involving the vaginal vault and inferiorly the lesion is seen involving the vulva. Multiple sub-centimetric left iliac and B/L inguinal lymphnodes noted.



**Figure 1:** Heterogeneously enhancing polypoidal T2 hyperintense lesion of size 45x43x86mm involving the vaginal vault and inferiorly the lesion is seen till introitus



**Figure 2:** 5x5x5cm sized mobile polypoidal growth seen in the right lateral and posterior wall of vagina till introitus



**Figure 3:** Mixture of hypercellular and hypocellular edematous areas with abundant small- to medium-sized vessels

Our multidisciplinary board decided to treat AMF of vagina with primary radiotherapy in view of aggressive recurrent unresectable disease. Patient received external beam radiation to local diseased area with margins to a dose of 50Gy in 25 fraction followed by boost dose of 30Gy in 5 fractions of interstitial brachytherapy from 24/May to 20/July/2016. Patient tolerated treatment well and during course of radiotherapy, she had developed skin grade II toxicities which were managed medically. Patient was kept on close follow up with clinical examination and remains with complete response for 20 months.

### 3. Discussion

A wide variety of mesenchymal lesions occur in the lower female genital tract (9,10). Broadly, these mesenchymal lesions can be separated into two groups. The first group includes several well characterized tumors that show a marked tendency to occur in the lower female genital tract, such as aggressive angiomyxoma, angiomyofibroblastoma (AMF) and cellular angiofibroma (11). These tumours can also be called as relatively site-specific. The second group embraces a wide range of heterogeneous lesions that frequently occur in this region, but arise in other anatomic sites as well, with examples, superficial cervicovaginal myofibroblastoma characterised by its numerous small- to medium-sized thick-walled vessels and negative staining for desmin. Other lesions that may be confused with SCVM include solitary fibrous tumour and mammary-type myofibroblastoma. Angio-myofibroblastoma of the lower female genital tract is diagnosed based on

clinical, radiological and morphological patterns treated primarily with surgery. Adjuvant therapy with radiotherapy in invasive forms may be recommended (12).

One should aim for complete resection, but incomplete or partial resection is acceptable, especially when high operative morbidity due to extensive surgery is anticipated and preservation of fertility is an issue. Long-term follow-up and careful monitoring with imaging techniques are essential for timely identification of recurrence. However, except for positive surgical margins, there are no clinical or histological predictors for tumour recurrence (13,14). The data in literature with limited number of patients with vaginal AMF reports 1-2 year of recurrence free survival (1,15). Most of these tumours show oestrogen and progesterone receptor positivity and are likely to be hormone dependent. Several beneficial results with gonadotropin-releasing hormone (GnRH) agonist have been described in primary treatment of small tumours, as adjuvant therapy for residual tumour, pre-operatively to shrink tumours or even in the treatment of recurrence (16,17). However, there are no conclusive data as to the effectiveness of hormonal therapy/oophorectomy in the treatment of these tumours (18). Due to low mitotic activity, radiotherapy or chemotherapy is unlikely to be a useful adjunct to primary surgery. Most authors did not notice any advantage of radiation therapy (19,20). Pre-operative external beam irradiation and intra-operative electron beam radiotherapy was used in one case to reduce risk of recurrence but follow-up data on the same are not available. Two cases of successful control of recurrent angiomyxoma with relatively high doses of external radiotherapy have also been reported (21,22). There are no supporting data for use of chemotherapy in patients with AMF.

Radiotherapy may be good alternative to surgery; for unresectable, medically inoperable or recurrent tumours, and also patients unresponsive to embolization or hormonal therapy requiring morbid surgery (23). This case report describes the unique role of definitive radiotherapy for recurrent unresectable angiomyofibroblastoma of vagina in a young woman; and remains complete response for 20 months.

### 4. Conclusions

We emphasize the role of definitive radiotherapy for patients with angiomyofibroblastoma of vagina and other pelvic sites that are not amenable for surgery, with benefits of good local control and organ preservation.

### References

- [1] Fletcher CD, Tsang WY, Fisher C, Lee KC, Chan JK. Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma. *Am J Surg Pathol* 1992; 16: 373-82.
- [2] Babala P, Biro C, Klacko M, Miklos P, Ondrus D (2011) Angiomyofibroblastoma of the cervix uteri: a case report. *Klin Onkol* 24(2): 133-136.
- [3] Morteale KJ, Lauwers GJ, Mergo PJ, Ros PR (1999) Perineal angiomyofibroblastoma: CT and MR findings

- with pathologic correlation. J Comput Assist Tomogr 23(5): 687-689.
- [4] Naheed S, Upadhyay K, Pradeep K (2011) Angiomyofibroblastoma of the vulva. J ObstetGynaecol 31: 554-555.
- [5] Lee SH, Yang JW, Do JM, Seo DH, Jung JH, et al. (2010) Angiomyofibroblastoma-like tumor of the scrotum. Korean J Urol 51(5): 365-367.
- [6] Lim KJ, Moon JH, Yoon DY, Cha JH, Lee IJ, et al. (2008) Angiomyofibroblastoma arising from the posterior perivesical space: a case report with MR findings. Korean J Radiol 9(4): 382-385.
- [7] Qiu P, Wang Z, Li Y, Cui G (2014) Giant pelvic angiomyofibroblastoma: case report and literature review. DiagnPathol 3(9):106.
- [8] Nasu K, Fujisawa K, Takai N, Miyakawa I. Angiomyofibroblastoma of the vulva. Int J Gynecol Cancer 2002; 12: 228-31.
- [9] McCluggage WG (2005) A review and update of morphologically blandvulvovaginal mesenchymal lesions. Int J GynecolPathol 24: 26-38.
- [10] Nucci MR, Fletcher CD (2000) Vulvovaginal soft tissue tumors: Update andreview. Histopathology 36: 97-108.
- [11] Steeper TA, Rosai J (1983) Aggressive angiomyxoma of the female pelvis andperineum. Report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J SurgPathol 7: 463-475.
- [12] Nucci MR, Granter SR, Fletcher CD (1997) Cellular angiofibroma: a benignneoplasm distinct from aggressive angiomyxoma. Am J SurgPathol 21: 636-644.
- [13] Wang Q, Zhao M, Lin X, Zhong W, Gao Y. Aggressive angiomyxoma of the vulva: intra-operative pathological diagnosis is useful in deciding the scope of surgery and reducing recurrence. ActaChir Belg. 2012;112(1):79-84.
- [14] Chan IM, Hon E, Ngai SW, Ng TY, Wong LC. Aggressive angiomyxoma in females: is radical resection the only option? ActaObstetGynecol Scand. 2000;79:216-20.
- [15] K. Nagai, K. Aadachi, and H. Saito, "Huge pedunculated angiomyofibroblastoma of the vulva," *International Journal of Clinical Oncology*, vol. 15, no. 2, pp. 201–205, 2010.
- [16] Ribaldone R, Piantanida P, Surico D, Boldorini R, Colombo N, Surico N. Aggressive angiomyxoma of the vulva. GynecolOncol. 2004;95(3):724-8.
- [17] Dahiya K, Jain S, Duhan N, Nanda S, Kundu P. Aggressive angiomyxoma of vulva and vagina: a series of three cases and review of literature. Arch Gynecol Obstet. 2011;283(5):1145-8.
- [18] Dierickx I, Deraedt K, Poppe W, Verguts J. Aggressive angiomyxoma of the vulva: a case report and review of literature. Arch Gynecol Obstet. 2008;277(6):483-7.
- [19] Magtibay PM, Salmon Z, Keeney GL, Podratz KC. Aggressive angiomyxoma of the female pelvis and perineum: a case series. Int J Gynecol Cancer. 2006;16(1):396-401.
- [20] Dove S, Remoué P, Valo I, Ybarlucea LR, Panel N, Fondrinier E. Unusual female pelvic tumour: aggressive angiomyxoma. Eur J ObstetGynecolReprod Biol. 2008;137(1):123-5.
- [21] Rhomberg W, Jasarevic Z, Alton R, Kompatscher P, Beer G, Breitfellner G. Aggressive angiomyxoma: irradiation for recurrent disease. StrahlentherOnkol. 2000;176(7):324-6. [ Links ]
- [22] Suleiman M, Duc C, Ritz S, Bieri S. Pelvic excision of large angiomyxoma in a woman: irradiation for recurrent disease. Int J Gynecol Cancer. 2006;16(Suppl 1):356-60.
- [23] Han-Geurts IJ, van Geel AN, van Doorn L, den Bakker M, Eggermont AM, Verhoef C. Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery. Eu J SurgOncol. 2006;32(10):1217-21.